-
EP4342468
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4342468
| EP4342468 - TOLEBRUTINIB SALT AND CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 23.02.2024 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 26.11.2022 | Most recent event Tooltip | 26.07.2024 | Change: Validation states | published on 28.08.2024 [2024/35] | 26.07.2024 | Change - extension states | published on 28.08.2024 [2024/35] | Applicant(s) | For all designated states Hangzhou Solipharma Co., Ltd. First Floor, 260 6th Ave Bldg 1 Qiantang New Area Hangzhou, Zhejiang 310018 / CN | [2024/13] | Inventor(s) | 01 /
SHENG, Xiaohong Hangzhou, Zhejiang 310018 / CN | 02 /
SHENG, Xiaoxia Hangzhou, Zhejiang 310018 / CN | 03 /
DAI, Yu Hangzhou, Zhejiang 310018 / CN | [2024/13] | Representative(s) | Müller-Boré & Partner Patentanwälte PartG mbB Friedenheimer Brücke 21 80639 München / DE | [2024/13] | Application number, filing date | 22804060.6 | 20.05.2022 | [2024/13] | WO2022CN94073 | Priority number, date | CN202110557261 | 21.05.2021 Original published format: CN202110557261 | CN202210156938 | 25.02.2022 Original published format: CN202210156938 | [2024/13] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022242740 | Date: | 24.11.2022 | Language: | ZH | [2022/47] | Type: | A1 Application with search report | No.: | EP4342468 | Date: | 27.03.2024 | Language: | EN | [2024/13] | Search report(s) | International search report - published on: | CN | 24.11.2022 | Classification | IPC: | A61K31/437, A61P35/00, A61P37/00, A61P29/00, A61P7/02 | [2024/13] | CPC: |
A61P7/02 (EP);
A61K31/4545 (EP);
A61K9/2866 (EP);
A61K9/4858 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
| C-Set: |
A61K31/4545, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/13] | Title | German: | TOLBRUTINIBSALZ UND KRISTALLFORM DAVON, HERSTELLUNGSVERFAHREN DAFÜR, PHARMAZEUTISCHE ZUSAMMENSETZUNG DARAUS UND VERWENDUNG DAVON | [2024/13] | English: | TOLEBRUTINIB SALT AND CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | [2024/13] | French: | SEL DE TOLÉBRUTINIB ET FORME CRISTALLINE CORRESPONDANTE, PROCÉDÉ DE PRÉPARATION CORRESPONDANT, COMPOSITION PHARMACEUTIQUE CORRESPONDANTE ET UTILISATION CORRESPONDANTE | [2024/13] | Entry into regional phase | 21.12.2023 | Translation filed | 21.12.2023 | National basic fee paid | 21.12.2023 | Search fee paid | 21.12.2023 | Designation fee(s) paid | 21.12.2023 | Examination fee paid | Examination procedure | 21.12.2023 | Examination requested [2024/13] | 09.07.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 29.05.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]EP2578585 (ONO PHARMACEUTICAL CO [JP]); | [A]CN104640861 (PHARMACYCLICS INC); | [X]CN105753863 (DONGGUAN ZHENXING BEITE MEDICAL TECH CO LTD); | [X]CN106459049 (PRINCIPIA BIOPHARMA INC); | [PX]WO2021150476 (GENZYME CORP [US]); | [PX]WO2022081512 (SYNUBI PHARMACEUTICALS LLC [US]) | by applicant | WO2016196840 |